Double-Target CAR-T: new hope for tough blood cancers?
NCT ID NCT06879262
Summary
This early-phase study is testing a new type of CAR-T cell therapy designed to attack two common targets (CD19 and CD22) on cancer cells. It aims to see if this approach is safe and effective for adults with B-cell acute lymphoblastic leukemia or non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Participants will receive a single infusion of these modified immune cells and be followed for three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R NHL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.